Range Impact sells cannabinoid drug unit Graphium for warrants and cash

RANGE IMPACT, INC.

Sold all Graphium common stock to Placer Biosciences, owned by former officers Dr. Zipp and Mr. McKilligan.
Consideration: warrants for 25% of Placer common stock (exercise price $0.01, expiring 2034), de minimis cash, 50% of equipment sale proceeds over 12 months.
Graphium held IP, permits, and lab equipment for early-stage cannabinoid therapeutics targeting Crohn’s disease and colitis.
Divestiture part of strategic shift to focus on acquiring, reclaiming, and repurposing mine land in Appalachia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.